The Century of Biology

On AI Infrastructure in Biology

Three stories; six parameters

Nov 23 • 

Elliot Hershberg

131

14

15

September 2025

Manifold Bio: Barcoded Biologics

Designing medicines that go where we want them to

Sep 28 • 

Elliot Hershberg

74

14

7

June 2025

What Are Virtual Cells?

Learning "universal representations" of life's fundamental unit

Jun 29 • 

Elliot Hershberg

105

10

11

March 2025

On Modality Commoditization

And what might come next

Mar 16 • 

Elliot Hershberg

120

5

9

February 2025

Hub-and-Spoke Biotechs: BridgeBio

Attempting "Moneyball for biotech"

Feb 16 • 

Elliot Hershberg

89

17

9

October 2024

Hub-and-Spoke Biotechs: Nimbus Therapeutics

Building an "evergreen" drug discovery engine

Oct 20, 2024 • 

Elliot Hershberg

61

16

6

September 2024

Living Carbon: Photosynthesis-Enhanced Trees

Why and how to engineer trees; climate biotech business strategy

Sep 22, 2024 • 

Elliot Hershberg

64

17

3

June 2024

A Summer Hiatus

Pausing before scaling

Jun 23, 2024 • 

Elliot Hershberg

57

9

Scaling CRISPR Cures

Realizing the potential of genetic medicine

Jun 2, 2024 • 

Elliot Hershberg

61

16

7

May 2024

Generating (Somewhat) New Biology with AI

Using protein language models for Digital Evolution

May 5, 2024 • 

Elliot Hershberg

55

16

2

April 2024

Compounding Until Inflection

Present vs. future platform value

Apr 14, 2024 • 

Elliot Hershberg

35

2

1

March 2024

Beyond Steel Tanks

GLP-1 drugs could one day outsell iPhones, but there is not enough biomanufacturing capacity to make them. For solutions, we should look away from the…

Published on Asimov Press • Mar 24, 2024